Naproxen

Nonsteroidal Anti-inflammatory Drug (NSAID) Propionic acid derivative

Dosage & Administration Guidelines

Species Route Dose Frequency Duration & Clinical Notes
Dog PO Historically 5 mg/kg initially, then 2 mg/kg every 48 hours, but this is no longer recommended due to high toxicity. Every 48 hours (if used, but not recommended) Duration: Short-term only; not recommended for chronic use.
Notes: Due to the extremely long half-life and narrow safety margin, naproxen is not recommended for use in dogs. Safer NSAIDs such as carprofen, meloxicam, or deracoxib are preferred.
Horse PO 10 mg/kg every 24 hours (not commonly used) Every 24 hours Duration: Short-term (3-5 days)
Notes: Not a preferred NSAID in horses; phenylbutazone or flunixin meglumine are more commonly used.

Clinical Indications & Species Uses

General Indications
  • Naproxen is not a first-line NSAID in veterinary medicine due to its long half-life and high risk of adverse effects in many species. It is primarily used in humans.
Dog (Canine)
  • Not recommended due to narrow safety margin and high toxicity risk; historically used for musculoskeletal pain and inflammation, but safer alternatives exist.
Cat (Feline)
  • Not recommended; extremely toxic to cats.
Cattle (Bovine)
  • Not approved; not recommended for use in food animals due to withdrawal times and toxicity risk.
Small Ruminants (Sheep / Goat)
  • Not recommended; no established safe dosage.
Rabbit & Small Mammals
  • Not recommended; risk of GI and renal toxicity.
Avian & Poultry
  • Not recommended; no established safe dosage.
Exotic & Other Species
  • Not recommended; no established safe dosage.

Pharmacology & Mechanism of Action

Drug Class: Nonsteroidal Anti-inflammatory Drug (NSAID) | Pharmacological Group: Propionic acid derivative

Mechanism of Action: Naproxen is a non-selective inhibitor of cyclooxygenase (COX-1 and COX-2) enzymes, thereby reducing the synthesis of prostaglandins from arachidonic acid. Prostaglandins are key mediators of inflammation, pain, and fever. By inhibiting their production, naproxen exerts anti-inflammatory, analgesic, and antipyretic effects. It also inhibits platelet aggregation by reducing thromboxane A2 synthesis.

Pharmacodynamics: Naproxen produces dose-dependent inhibition of prostaglandin synthesis. Its anti-inflammatory effect is comparable to other NSAIDs, but it has a relatively long half-life in humans, which may not translate to veterinary species. In dogs, naproxen has a very long half-life (up to 74 hours), leading to a narrow safety margin and a high risk of toxicity with repeated dosing. It is more potent than aspirin but less selective for COX-2 compared to newer NSAIDs.

⚡ Pharmacokinetics Summary

Absorption: Naproxen is well absorbed after oral administration in most species. In dogs, peak plasma concentrations occur within 2-4 hours. Food may delay absorption but does not significantly affect overall bioavailability.
Distribution: Naproxen is highly protein-bound (>99%) in plasma, primarily to albumin. It distributes widely into tissues and synovial fluid, where concentrations may be lower than plasma but persist longer. It crosses the placenta and is excreted in small amounts in milk.
Metabolism: Naproxen is extensively metabolized in the liver, primarily via demethylation and glucuronide conjugation. The metabolites are pharmacologically inactive. In dogs, metabolism is slow, contributing to the long half-life.
Excretion: Naproxen and its metabolites are excreted primarily in the urine (about 95%) and to a small extent in feces. In dogs, renal excretion is a major route, and impaired renal function can lead to accumulation and toxicity.
Half-Life: Dog: 35-74 hours; Cat: ~35 hours (but not recommended); Horse: ~4 hours; Cattle: ~4-6 hours (not approved); Humans: 12-17 hours.
Bioavailability: Oral bioavailability is nearly complete in dogs and humans (>95%). In horses, oral bioavailability is approximately 50%.
Protein Binding: >99% (primarily albumin)

Available Formulations & Strengths

Oral Tablet 220 mg, 250 mg, 275 mg, 375 mg, 500 mg (PO)
Oral Suspension 125 mg/5 mL (PO)
Delayed-Release Tablet 375 mg, 500 mg (PO)

Contraindications & Clinical Warnings

Contraindications:
  • Known hypersensitivity to naproxen or other NSAIDs
  • Active gastrointestinal ulceration or bleeding
  • Renal or hepatic impairment
  • Pregnancy (especially late gestation) unless benefits outweigh risks
  • Concurrent use of other NSAIDs or corticosteroids
  • Dehydrated, hypovolemic, or hypotensive patients
  • Bleeding disorders or concurrent anticoagulant therapy
Warnings & Clinical Precautions:
  • Do not use in cats due to extreme toxicity.
  • Use with extreme caution in dogs; safer alternatives are strongly recommended.
  • Monitor renal function, liver enzymes, and gastrointestinal signs during therapy.
  • Avoid use in animals with pre-existing renal, hepatic, or cardiac disease.
  • Use the lowest effective dose for the shortest duration.
  • Provide adequate hydration during therapy.
  • Do not exceed recommended dose or frequency; accumulation can occur due to long half-life.
  • In food animals, observe withdrawal times; naproxen is not approved for use in food animals.

Adverse Effects & Reactions

Common:

  • Gastrointestinal upset (vomiting, diarrhea, anorexia)
  • Lethargy
  • Increased thirst and urination

Serious / Severe:

  • Gastrointestinal ulceration and perforation
  • Renal papillary necrosis and acute kidney injury
  • Hepatotoxicity
  • Bone marrow suppression
  • Seizures (in overdose)

Rare:

  • Allergic reactions (skin rash, anaphylaxis)
  • Blood dyscrasias
  • Neurological signs (ataxia, tremors)

Key Drug Interactions

Interacting Drug / Class Clinical Effect & Mechanism Severity
Other NSAIDs (e.g., aspirin, carprofen, meloxicam) Additive risk of gastrointestinal ulceration and renal toxicity. High
Corticosteroids (e.g., prednisone, dexamethasone) Increased risk of gastrointestinal ulceration and perforation. High
Anticoagulants (e.g., warfarin, heparin) Increased risk of bleeding due to platelet inhibition and gastric irritation. High
Diuretics (e.g., furosemide) Reduced diuretic efficacy and increased risk of renal toxicity. Moderate
ACE inhibitors (e.g., enalapril) Reduced antihypertensive effect and increased risk of renal impairment. Moderate
Methotrexate Increased methotrexate toxicity due to reduced renal clearance. High

Overdose & Toxicity Management

Signs of Toxicity:

  • Vomiting (often with blood)
  • Diarrhea
  • Lethargy
  • Depression
  • Ataxia
  • Seizures
  • Acute kidney injury (oliguria/anuria)
  • Gastrointestinal ulceration and perforation
  • Coma

Emergency Treatment Protocol: Induce emesis if within 2 hours of ingestion and the animal is conscious. Administer activated charcoal to reduce absorption. Provide aggressive supportive care: intravenous fluids to maintain renal perfusion, gastrointestinal protectants (e.g., sucralfate, H2 antagonists or proton pump inhibitors), and monitor renal and hepatic function. In severe cases, consider hemodialysis or peritoneal dialysis. There is no specific antidote for naproxen toxicity.

Food Animal Withdrawal Times

Naproxen is not approved for use in food animals in the United States. If used extra-label, a withdrawal time of at least 30 days for meat and 7 days for milk is suggested, but due to lack of data, a conservative approach is recommended. Consult regulatory authorities.

Storage, Handling & Regulatory Information

Storage Temperature: Store at room temperature (20-25°C, 68-77°F).

Handling & Special Conditions: Protect from moisture. Keep in a tightly closed container.

Dispensing Status: Prescription Required (Rx Only)

Approval Status: Not approved for veterinary use in the US; approved for human use.

Extra-Label (Off-Label) Use: In the US, naproxen is not FDA-approved for veterinary use. Extra-label use in animals is permitted under AMDUCA (Animal Medicinal Drug Use Clarification Act) only by or on the order of a licensed veterinarian within a valid veterinarian-client-patient relationship, and only when no approved animal drug is available. Use in food animals requires extended withdrawal times and careful residue monitoring.

Clinical Pearls & Practice Notes

💡 Clinical Insights: Naproxen is a potent NSAID with a long half-life in dogs, making it particularly dangerous due to the risk of accumulation and toxicity. It is not recommended for use in veterinary medicine, especially in cats, where it can cause severe renal and gastrointestinal damage even at low doses. Safer alternatives such as carprofen, meloxicam, deracoxib, and firocoxib are preferred for dogs. In horses, naproxen is occasionally used but is not a first-line choice. Always consider the individual patient's health status, and monitor for adverse effects. If naproxen is the only option, use extreme caution, administer the lowest effective dose, and monitor closely. For pain management in animals, consult current veterinary guidelines and choose approved NSAIDs with established safety profiles.

References & Literature

  • 📚 Plumb's Veterinary Drug Handbook
  • 📚 Papich Veterinary Pharmacology and Therapeutics
  • 📚 Compendium of Veterinary Products (CVP)